Comparison of testing methods assessing the in vitro efficacy of the combination of aztreonam with avibactam on multidrug-resistant Gram-negative bacilli

Author:

Deckers Corentin1,Bélik Florian1,Denis Olivier1,Bogaerts Pierre1,Montesinos Isabel1,Berhin Catherine1,Bouchahrouf Warda1,Hoebeke Martin1,Evrard Stéphanie1,Gilliard Nicolas1,Okur Merve1,Huang Te-Din1

Affiliation:

1. National Reference Center for Antibiotic-Resistant Gram-Negative Bacilli, CHU UCL Namur and Université Catholique de Louvain.

Abstract

Abstract Background Aztreonam-avibactam (ATM-AVI) combination shows promising effectiveness on most carbapenemase-producing Gram-negatives, yet standardized antibiotic susceptibility testing (AST) methods for evaluating the combination in clinical laboratories is lacking. We aimed to evaluate different ATM-AVI AST approaches.Methods 96 characterized carbapenem-resistant clinical isolates belonging to 9 Enterobacterales (EB; n = 80) and P. aeruginosa (PA; n = 16) species, including 90 carbapenemase producers and 72 strains resistant to both CAZ-AVI and ATM, were tested. Paper disk elution (DE; Bio-Rad) and E-test gradient strips stacking (SS; bioMérieux) were performed for the ATM + CAZ-AVI combination. MIC Test Strip (MTS; Liofilchem) was evaluated for ATM-AVI MIC determination. Results were interpreted applying ATM clinical breakpoints of the EUCAST guidelines to assess the combinations and compared to the broth microdilution (BMD) method using Sensititre panels (Thermofisher).Results According to the reference BMD, 93% of EB and 69% of PA were tested susceptible to ATM-AVI. The synergistic effect of ATM-AVI was of 95% for EB, but of only 17% for PA. Higher categorical and essential agreement (CA / EA) rates were obtained with the MTS method for both EB (89% / 91%) and PA (94% / 94%) compared to those of SS (87% / 83% for EB; 81% / 81% for PA). MTS and SS yielded 2 and 3 major discrepancies (MD), respectively, while 3 very major discrepancies (VMD) each were observed for both methods. Concerning the DE method, CA reached 91%, for EB and 81% for PA, but high number of VMD were observed for EB (n = 6; 8%) and for PA (n = 3; 19%).Conclusions The ATM-AVI association displayed excellent in vitro activity against highly resistant clinical Enterobacterales strains. MTS method offers accurate ATM-AVI AST results, while the SS method might serve as better alternative then DE method in assessing the efficacy of ATM + CAZ-AVI combination. However, further investigation is needed to confirm the methods' ability to detect ATM-AVI resistance.

Publisher

Research Square Platform LLC

Reference27 articles.

1. Efficacy., Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria. ClinicalTrials.gov ID NCT03580044.

2. A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria. (REVISIT). ClinicalTrials.gov ID NCT03329092

3. Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-beta-lactamase-Producing Enterobacterales;Falcone M;Clin Infect Dis,2021

4. Can Ceftazidime-Avibactam and Aztreonam Overcome beta-Lactam Resistance Conferred by Metallo-beta-Lactamases in Enterobacteriaceae?;Marshall S;Antimicrob Agents Chemother,2017

5. Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing Enterobacterales in the Antibiotic Resistance Laboratory Network, March 2019 to December 2020;Bhatnagar A;Antimicrob Agents Chemother,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3